Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
nepafenac (Nevanac®)
Reference No. 1509
Publication date:
16/08/2013
Last review date:
30/09/2016
Appraisal information
nepafenac (Nevanac®) 1 mg/ml eye drops
Company:
Alcon Laboratories (UK) Ltd
BNF category:
Eye
NMG meeting date:
19/06/2013
AWMSG meeting date:
17/07/2013
Submission Type:
Full Submission
Status:
Recommended
Advice No:
1813
Ratification by Welsh Government:
14/08/2013
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Nepafenac (Nevanac®) is recommended for use within NHS Wales for reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
Final Appraisal Recommendation (FAR)
Download
nepafenac (Nevenac) 1509 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
nepafenac (Nevanac) 1509 ASAR
Clinical Expert (CE) Summary
Download
nepafenac (Nevanac) 1509 CE summary